Oncology Ventures in-licensed DRP tool for drug development to be studied by MPI as tool for Personalized Medicine in breast cancer

Hoersholm, Denmark, September 14th, 2016 – Oncology Venture Sweden AB (OV:ST) today announced that its Drug Response Predictor DRP™ tool in-licensed from Medical Prognosis Institute (MPI) for drug development is to be studied by MPI as a tool for Personalized Medicine – Personalized Response Prediction – PRP™. A study is set up in collaboration with Breast Cancer Experts at Danish oncology departments. The database for hosting the clinical data on approximately 800 metastatic breast cancer patients has obtained approval from Datatilsynet (Data Protection Agency) as well as from the Danish Ethics Committee. The patients’ tumors to be investigated are selected from a data set of > 1100 Danish Breast Cancer patients. The aim of the study is to investigate the PRPs ability to predict whether a patient would respond or not to anticancer treatments given during their disease.
If the PRP for Personalized Medicine with statistical significance can predict treatment outcome for the individual cancer patient this will be very supportive for the DRP technology’s potential for the use in drug development.

“The objective of the MPI study is to evaluate whether the PRP in practice can predict drug sensitivity to Fulvestrant, epirubicin and vinorelbine + trastuzumab in patients with metastatic breast cancer by comparing the results of the PRPs with the patient’s clinical response to a particular drug,” says Peter Buhl Jensen, M.D., CEO of Oncology Venture. “If successful this will be a very supportive for the DRP tool used in Oncology Venture for drug development as it builds on the same technology platform,” Buhl Jensen further comments .

About the Drug Response Predictor - DRP™ screening tool  

Oncology Venture uses the MPI multi gene DRP™ to select those patients that by the gene signature in their cancer is found to have a high likelihood of response to the drug. The goal is to develop the drug for the right patients and by screening patients before treatment the response rate can be significantly increased.This DRP™ method builds on the comparison of sensitive vs. resistant human cancer cell lines including genomic information from cell lines combined with clinical tumor biology and clinical correlates in a systems biology network. The DRP™ is based on messenger RNA from the patients biopsies.
The DRP™ platform i.e. the DRP™ and the PRP™ tools can be used in all cancer types, and is patented for more than 60 anti-cancer drugs in the US. The PRP™ is used by MPI for Personalized Medicine. The DRP™ is used in Oncology Venture for drug development.

For further information, please contact

Ulla Hald Buhl , COO and
Chief IR & Communications
Mobile:+45 2170 1049
uhb@oncologyventure.com
or Peter Buhl Jensen , CEO
Mobile: +45 21 60 89 22
E-mail: pbj@oncologyventure.com 

This information is information that Oncology Venture Sweden AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on 14th September 2016.

About Oncology Venture Sweden AB  

Oncology Venture Sweden AB is engaged in the research and development of anti-cancer drugs via its wholly owned Danish subsidiary Oncology Venture ApS. Oncology Venture has a license to use Drug Response Prediction – DRP™ – in order to significantly increase the probability of success in clinical trials. DRP™ has proven its ability to provide a statistically significant prediction of clinical outcomes from drug treatment in cancer patients in 29 of the 37 clinical studies that were examined. The Company uses a model that alters the odds in comparison with traditional pharmaceutical development. Instead of treating all patients with a particular type of cancer, patients’ tumors genes are screened first and only those who are most likely to respond to the treatment will be treated. Via a more well-defined patient group, the risk and costs are reduced while the development process becomes more efficient.
The current product portfolio: LiPlaCis for Breast Cancer, Irofulven developed from a fungus for prostate cancer and APO010 – an immuno-oncology product for Multiple Myeloma.

Subscribe

Documents & Links